Table 2.

Recommendations for the pharmacological management of IBD after the peak of the COVID-19 pandemic (adapted from the SIGENP position paper) [16]

Topic	Recommended
Steroids for induction	Yes (accelerated steroid weaning if clinically indicated)
Suspension of immunomodulators
▪As monotherapy	No
▪As combination therapy	No
Suspension of biologics
▪As monotherapy	No
▪As combination therapy	No
Start of immunosuppressants or anti-TNF-α	Yes
Intervals and doses of anti-TNF-α	Regular
RT-PCR/serological screening for SARS-CoV-2 before starting anti-TNF-α therapy	No
Vedolizumab and ustekinumab use	Yes (not contraindicated)

TNF-α, tumor necrosis factor-α; RT-PCR, real time-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2